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imaging has been demonstrated to quantify hepatic fibrosis, iron,
and steatosis. The aim of this study was to determine if MR can be
used to predict negative clinical outcomes in liver disease
patients.
Methods: Patients with chronic liver disease (n = 112) were
recruited for MR imaging and data on the development of liver
related clinical events were collected by medical records review.
The median follow-up was 27 months. MR data were analysed
blinded for the Liver Inflammation and Fibrosis score (LIF; <1,
1–1.99, 2–2.99, and P3 representing normal, mild, moderate,
and severe liver disease, respectively), T2 for liver iron content
and proportion of liver fat. Baseline liver biopsy was performed
in 102 patients.
Results: Liver disease aetiologies included non-alcoholic fatty
liver disease (35%) and chronic viral hepatitis (30%). Histologi-
cally, fibrosis was mild in 54 (48%), moderate in 17 (15%), and
severe in 31 (28%) patients. Overall mortality was 5%. Ten
patients (11%) developed at least one liver related clinical event.
The negative predictive value of LIF <2 was 100%. Two patients
with LIF 2–2.99 and eight with LIFP3 had a clinical event.
Patients with LIFP3 had a higher cumulative risk for developing
clinical events, compared to those with LIF <1 (p = 0.02) and LIF
1–1.99 (p = 0.03). Cox regression analysis including all 3 variables
(fat, iron, LIF) resulted in an enhanced LIF predictive value.
Conclusions: Non-invasive standardised multiparametric MR
technology may be used to predict clinical outcomes in patients
with chronic liver disease.Journal of Hepatology 20
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Liver disease in Western populations has reached epidemic pro-
portions, where a third of all adults have some degree of non-
alcoholic fatty liver disease (NAFLD) [1]. The estimates for the
prevalence of non-alcoholic steatohepatitis (NASH), the more
aggressive form of NAFLD, are as high as 12% [2]. Furthermore,
viral hepatitis affects over 450 million people worldwide [3,4],
and is associated with cirrhosis in 20% of this population. After
developing cirrhosis, patients may remain well (‘‘compensated”)
for long periods of time, but approximately 5–7% will develop
complications (become ‘‘decompensated”) annually. Further-
more, annual mortality rates can be as high as 57% once cirrhosis
is established [5]. In the face of this epidemic, there is an urgent
clinical need for technologies that can identify patients with
chronic liver disease, and risk stratify those who will develop
complications or die from liver disease. This will facilitate timely
therapeutic interventions, liver transplantation, and stratification
within clinical studies.
Traditionally, clinicians have used needle biopsy to assess
liver fibrosis. However, as this procedure is painful, requires hos-
pitalisation for several hours or more, and is associated with a
risk of complications and death, non-invasive methods for liver
fibrosis assessment have been developed in the last decade. Fur-
thermore, liver biopsy is associated with both sampling and
observer dependent variability [6,7]; therefore the use of this as
a gold standard comparator for the development of non-
invasive technologies is sub-optimal [8]. A more robust and clin-
ically relevant approach would involve the assessment of
whether non-invasive technologies can be used to predict clini-
cally meaningful endpoints.
Broadly, non-invasive techniques can be divided into those
based on direct and indirect serum markers of fibrosis and those
based on imaging and or elastography. Serum biomarkers are
attractive as they are easy to measure and can be repeated over16 vol. 64 j 308–315
!123 patients consented to multiparametric 
MR (T1, T2* mapping) for calculation of LIF 
score (fibrosis),  T2* (liver iron) and 1H-MRS 
(liver fat content)
6 patients excluded
- Claustrophobic 
(n = 2)
- Incomplete MR 
data sets (n = 4)*
117 patients had full multiparametric
MR data sets
112 patients included in final analysis
102 (91%) had no liver 
related endpoints
Lost to follow-up
(n = 5)
10 (9%) had at least one liver 
related endpoint
Ascites (n = 4)
Hepatic encephalopathy (n = 3)
Hepatocellular carcinoma (n = 1)
Liver related deaths (n = 2)
Fig. 1. Study flow chart. The Liver Inflammation and Fibrosis (LIF) score is a
standardised continuous score (0–4) derived from liver T1 and T2 values. T1
primarily reflects the amount of extracellular fluid and can change with
inflammation and fibrosis and T2 primarily reflects the amount of iron deposition.
Liver iron has a confounding effect on T1, and this is accounted for in the LIF score
calculation.
⁄
Liver iron concentration from T2 maps and hence LIF calculation was
not possible in 4 cases. MR, magnetic resonance; 1H-MRS: proton (1H) magnetic
resonance spectroscopy; LIF, Liver Inflammation and Fibrosis score.
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time. However, they lack specificity as they may be affected by
extrahepatic fibrosis. For example, the Extended Liver Fibrosis
(ELF) panel reported a sensitivity of 90%, but had a specificity of
only 41%, with an area under the receiver operating characteristic
curve of 0.80 for the detection of severe fibrosis [9]. A subsequent
7 year follow-up study suggested that ELF score could predict
clinical outcomes [10]. However, patients with any disorder asso-
ciated with extrahepatic fibrosis were excluded from these stud-
ies making it difficult to assess how this test could be applied to a
general, unselected population.
Liver stiffness measurement using magnetic resonance elas-
tography (MRE), ultrasound-based transient elastography
(FibroscanTM), or acoustic radiation force impulse have also been
used to assess fibrosis and for predicting clinical outcomes [11–
15]. However, ultrasonic elastography cannot be used if there is
significant fat or fluid between the chest wall and the liver; failed
readings or unreliable results are observed in nearly 20% of
patients, particularly those with obesity and the metabolic syn-
drome [16]. Furthermore, elastography measures have been
shown to carry considerable variance [17]. MRE is more accurate
than transient elastography [18], but needs additional hardware
and is compromised in patients with haemosiderosis.
Overall, despite these advances in non-invasive liver assess-
ment, the drawbacks of the currently available techniques mean
that they are not widely available and have not been validated for
use as surrogate endpoints in clinical trials. Because of this, sev-
eral professional and regulatory bodies recognise the need for
better stratification tools [19–21].
Magnetic resonance (MR) techniques offer an attractive non-
invasive option for liver assessment. These are well established
in assessing anatomical morphology, are organ specific and have
the capacity to evaluate the whole organ thereby eliminating all
the concerns around sampling error. Furthermore, they can be
standardised across scanner vendors and magnet strengths so
that inter-operator variability is negligible.
T1 mapping is a MR technique that allows in vivo tissue char-
acterisation. At our centre, a multiparametric MR technique has
been established, that includes T1 mapping for fibrosis/inflamma-
tion imaging, T2 mapping for liver iron quantification and proton
magnetic resonance spectroscopy (1H-MRS) for liver fat quantifi-
cation. The T1 measurements in our method are adjusted for the
iron level, as high iron levels in the presence of fibrosis can lead
to ‘‘pseudo-normal” T1 values. This is a quick and truly non-
invasive test that does not require injection of any intravenous
contrast agent. In a recent study, it has shown good correlation
with histological parameters in a cohort of patients with mixed
liver disease aetiologies undergoing clinically indicated liver
biopsy [22].
The aim of the present study was to assess whether data
obtained from this multiparametric MR protocol could be used
to predict all-cause mortality and liver related clinical events,
irrespective of stage of fibrosis or disease aetiology.Patients and methods
Study design and patient population
The population under study were those scheduled to have a clinically indicated
liver biopsy (n = 116) and adult patients who had cirrhosis diagnosed on biopsy
within 5 years of their MRI scan (n = 7). Patients were included irrespective of
underlying liver disease aetiology or disease stage. The only exclusion criterionJournal of Hepatology 201was the presence of MRI contraindications. Patients were recruited from two
UK centres (Oxford and Reading) between April 2011 and August 2013. All
patients were followed for the development of clinical outcomes except those
who were lost to follow-up or had incomplete MR data (n = 11; Fig. 1). Baseline
data were collected at the time of recruitment. Outcome data were collected
through review of the individual electronic and paper patient records.
The study was approved by the UK National Research Ethics Service and the
institutional review board and was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. All patients gave written informed
consent.
All-cause mortality and liver related clinical events
Both all-cause mortality and liver related clinical events were evaluated. Liver
related clinical events were defined as liver related death, the development of
hepatocellular carcinoma (HCC) and any new episode of hepatic decompensation
(clinically evident ascites, variceal bleeding, and hepatic encephalopathy).
Although more than one event per patient was possible and occurred, patients
were only counted once in the analysis at the time of the first liver related clinical
event. Patients who had evidence of liver related complications at or before enrol-
ment were only counted again if they developed a complication that was distinct
from that observed before enrolment, or died. Patients were followed up until
their last clinical review or until they died, but the index liver related event as
defined above was used in the analysis.
Multiparametric MRI
The MRI technique used in this study has been previously described [22]. Briefly,
MR scans were performed in Oxford using a 3-Tesla scanner (Tim Trio, Siemens
Healthcare, Germany). Transverse abdominal T1 and T2 MR maps were acquired
for the estimation of extracellular fluid and liver iron respectively. Proton mag-
netic resonance spectroscopy (1H-MRS) was also used to measure liver fat con-
tent. Patients attended for their MRI scans after fasting for at least 4 h.6 vol. 64 j 308–315 309
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Iron corrected T1 and the Liver Inflammation and Fibrosis score
T1 relaxation time increases with increases in extracellular fluid such as in fibro-
sis and inflammation. However, the presence of iron, which can be accurately
measured from T2 maps, has an opposing effect on the T1. An algorithm has been
created that allows for the bias introduced by elevated iron to be removed from
the T1 measurements, yielding the iron corrected T1 (cT1). This has been described
in detail previously [22,23]. This correction was necessary in 54% of patients in
this study that were found to have a liver T2 <19 ms, corresponding to a dry
weight liver iron concentration of >1.3 mg/g, indicating some degree of iron over-
load, which affects T1 measurements.
Optimal cT1 cut-off points for the differentiation of: no (Ishak fibrosis stage
F0), mild (Ishak F1–2), moderate (Ishak F3–4), and severe (Ishak F5–6) fibrosis
have been derived from the association of cT1 with histological fibrosis in our pre-
vious study [22]. These cut-offs were used to develop the Liver Inflammation and
Fibrosis (LIF) score, a standardised continuous score (0–4) which can be derived
from many MR systems. For this study, patients were categorised according to
LIF score into having: no (LIF <1), mild (LIF 1–1.99), moderate (LIF 2–2.99), or sev-
ere (LIF 3–4) liver disease.
LiverMultiScanTM (LMS, Perspectum Diagnostics, Oxford, UK), is a software
product, developed specifically to measure cT1 and LIF scores from T1 and T2
maps. For this study, LMS was used to analyse anonymised images off-site, by
investigators blinded to the clinical and histological data. LIF scores were mea-
sured in a single, operator-defined, region of interest in the right liver lobe, away
from vascular and biliary structures. Representative LMS images are shown in
Fig. 2.
Statistical analysis
The primary variable of interest was the LIF score measured using LMS. Patients
were stratified according to LIF severity as described above. Secondary variables
were liver iron measured by T2 and liver fat measured by 1H-MRS. Cut-off values
derived from our previous study [22] were used to define two severity categories
for iron (high liver iron: T2 612.5 ms, low liver iron: T2 >12.5 ms) and 3 cate-
gories for fat fraction (0: fat <1.5%, 1: fat 1.5– <7.5%, 2: fatP7.5%). The cut-off
for defining the iron severity categories represents the best threshold for identi-
fying those with any grade of histological iron deposition and corresponds to aLIF
LIF = 0.8 LIF = 1.4
LIF = 2.7 LIF = 3.2
Fig. 2. Examples of LiverMultiScan MR data. Representative images from
patients in each Liver Inflammation and Fibrosis (LIF) severity category, produced
by analysis of the raw data using LiverMultiScan. LIF was measured in operator
chosen regions of interest in the right liver lobe, in the liver parenchyma, away
from vascular and biliary structures. The LIF scores measured for each image in
this figure are indicated under each image. The predefined colour scale used to
generate these maps is also included. LIF, Liver Inflammation and Fibrosis score.
(This figure appears in colour on the web.)
310 Journal of Hepatology 201dry weight iron 1.7 mg/g. The cut-offs for defining the liver fat categories repre-
sent the best thresholds for identifying those with no steatosis (fat fraction <1.5%)
and those with steatosis in more than 66% of hepatocytes (steatosis grade 3; fat
fraction P7.5%). The primary outcome was the index liver related event as
described above (liver related death, HCC, clinically evident ascites, encephalopa-
thy, variceal bleeding). Subgroup analysis including only patients with compen-
sated disease at baseline was also carried out.
Descriptive statistics were used to summarise the subjects’ baseline charac-
teristics for different LIF categories. The Shapiro–Wilks test was used to test for
normality of the data across the whole cohort. Analysis of variance was used to
test for differences between multiple groups. Kaplan–Meier analysis was used
to establish the proportions of patients in each LIF, fat and iron severity category
that remained free of liver related events in the follow-up period. Differences
between the curves were compared using the log-rank test. Cox regression anal-
ysis was used to examine the additive effects of LIF, liver fat and liver iron (mea-
sured by T2) on predicting liver related events. The level of statistical significance
was set at p <0.05. The analysis was carried out using SPSS v22 (Armonk, NY; IBM
Corp) software. The GraphPad Prism software (v6.04) was used to generate the
Kaplan–Meier curves for the illustration in the figures.Results
Baseline characteristics
During the study period 123 patients consented to take part. Six
were excluded due to claustrophobia (n = 2) or incomplete MR
data (n = 4). Follow-up data were available for 112 of the 117
patients with complete MR data sets (Fig. 1). Patients were lost
to follow-up either because they moved out of the area, or they
did not return for any further clinical follow-up after their MR
scan. The median (IQR) follow-up period was 27 (15–31) months.
The majority of patients were male (n = 71, 79%) and the mean
(±SD) age was 51 (±13.8) years. Eight (7%) patients had evidence
of decompensation at or prior to enrolment, and 16 (14%)
patients received treatment for their underlying disease in the
follow-up period (6 patients with chronic hepatitis C virus infec-
tion achieved sustained virological response, 7 patients with
chronic hepatitis B achieved viral suppression on treatment and
three patients with obesity had weight reduction surgery). Base-
line clinical, histological, and biochemical characteristics for the
whole cohort and for the four LIF severity categories are sum-
marised in Table 1.
Liver biopsy was performed in 102 patients. All patients had
evidence of chronic liver disease. Chronic viral hepatitis and
NAFLD were the two most common histological diagnoses affect-
ing 34 (30%) and 39 (35%) patients, respectively. Histologically,
liver fibrosis was assessed using the Ishak score [24], and staged
as mild (F0–2) in 54 (48%), moderate (F3–4) in 17 (15%), and sev-
ere (F5–6) in 31 (28%) patients.
When patients were stratified using the LIF score; 38 (34%)
had severe disease, 18 (16%) had moderate disease, 34 (30%)
had mild disease, and 22 (20%) had no liver disease. More
patients with high LIF scores had severe histological fibrosis
(LIF 3–4: 50%, LIF 2–2.99: 44%, LIF 1–1.99: 12%, LIF <1: 0%,
p <0.001). Furthermore, patients with high LIF scores had higher
BMI (LIF 3–4: 29.2 kg/m2, LIF 2–2.99: 27.1 kg/m2, LIF 1–1.99:
26 kg/m2, LIF <1: 27.1 kg/m2, p = 0.02), higher liver fat content
(LIF 3–4: 17.6%, LIF 2–2.99: 7.1%, LIF 1–1.99: 8.2%, LIF <1: 3.5%,
p = 0.01) and were more likely to have type 2 diabetes (LIF 3–4:
24%, LIF 2–2.99: 28%, LIF 1–1.99: 6%, LIF <1: 0%, p = 0.04).
Seven out of the eight patients who had baseline decompen-
sation had severe disease by LIF criteria (LIFP3) and four of these
went on to develop further liver related clinical events. One
patient with baseline decompensation (ascites) had mild disease6 vol. 64 j 308–315
Table 1. Baseline patient characteristics.
All (n = 112) LIF <1 (n = 22) LIF 1-1.99 (n = 34) LIF 2-2.99 (n = 18) LIF 3-4 (n = 38) p value
Age; years (mean ± SD)  51 ± 13.8 47.6 ± 12 49.3 ± 16 52.8 ± 10 51.7 ± 12.4 0.5
Male; n (%)  79 (71) 15 (71) 25 (74) 17 (94) 22 ( 58) 0.04
BMI; kg/m2 (median; IQR)  27.5
 (24.7-30.7)
27.1
(24.0-28.6)
26
(23.4-28.5)
27.1
(25.2-32.9)
29.2
(26.3-34)
0.02
T2DM; n (%)  16 (14) 0 2 (6) 5 (28) 9 (24) 0.04
Excessive alcohol; n (%)  27 (24) 5 (23) 4 (12) 5 (28) 13 (34) 0.47
Decompensation at baseline; n (%)  8 (7) 0 1 (3) 0 7 (18) 0.03
Treatment for the underlying disease in the 
follow-up period; n (%)
 16 (14) 3 (14) 7 (21) 4 (22) 2 (38) 0.21
Mean (± SD) liver fat content by 1H-MRS (%)  10.3 (12.6) 3.5 (3.3) 8.2 (10.8) 7.1 (7.6) 17.6 (15.3) 0.01
Mean (± SD) T2* (ms)  17.8 (6.6) 19.2 (5.4) 17.8 (6.4) 17.5 (7.3) 17.2 (7.1) 0.74
Primary histological diagnosis; n (%)
Viral hepatitis 34 (30) 5 (23) 15 (44) 6 (33) 8 (21) 0.02
NAFLD 39 (35) 5 (23) 8 (24) 9 (50) 17 (45)
ASH 12 (10) 1 (5) 1 (3) 2 (11) 8 (21)*
PSC/PBC/AIH 7 (6) 3 (14) 2 (6) 1 (6) 1 (3)
Other+ 10 (9) 5 (23) 4 (12) 0 1 (3)
No biopsy 10 (9) 3 (14) 4 (12) 0 3 (8)
Histological fibrosis; Ishak stage; n (%)
Mild; F0-2 54 (48) 18 (82) 17 (50) 9 (50) 10 (26) <0.001
Moderate; F3-4 17 (15) 1 (5) 9 (26) 1 (6) 6 (16)
Severe; F5-6 31 (28) 0 4 (12) 8 (44) 19 (50)
No biopsy 10 (9) 3 (14) 4 (12) 0 3 (8)
Blood results; (median; IQR)
Bilirubin (µmol/L) 12 
(8-17)
10.5 
(6-14.5)
10 
(7-16.5)
12.5 
(8-24)
12 
(8-18)
0.55
ALT (IU/L) 60 (35-99) 57 (38-97) 40 (29-80) 70 (35-86) 78 (37-126) 0.21
ALP (IU/L) 200
(161-288)
191
(145-321)
200
(157-253)
205
(156-290)
206
(168-300)
0.93
Albumin (g/L) 45 (43-47) 46 (44-47) 45 (43-46) 45 (43-48) 44 (40-46) 0.13
GGT (IU/L) 78
(36-153)
51
(28-131)
47 
(26-59)
81 
(48-243)
100 
(65-230)
0.006
AST (IU/L) 46 (31-76) 36 (31-57) 33 (26-59) 53 (32-96) 66 (41-112) 0.001
Platelet count (x109/L) 188
(152-248)
203
(179-266)
205
(155-257)
181
(133-212)
167
(144-240)
0.11
Prothrombin time (s) 13.8
(13-14.6)
13.3
(12.9-14.1)
13.6
(13-14.2)
13.4
(12.9-14.7)
14.5
(13.5-15.6)
0.001
p values quoted for the differences between the 4 LIF severity groups.
One patient in this subgroup had alcoholic hepatitis and cirrhosis on biopsy.
+Other included: non-specific cholestasis (n = 4), no specific diagnostic features (n = 2), sarcoid (n = 1), sinusoidal dilatation (n = 1), cryptogenic cirrhosis (n = 1),
haemochromatosis (n = 1).
LIF, Liver Inflammation and Fibrosis score; SD, standard deviation; IQR, inter-quartile range; BMI, body mass index; T2DM, type 2 diabetes mellitus; 1H-MRS, proton
magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; ASH, alcoholic steatohepatitis; PSC, primary sclerosing cholangitis; PBC, primary biliary
cirrhosis; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; AST, aspartate aminotransferase.
JOURNAL OF HEPATOLOGYby LIF criteria (LIF 1–1.99) and remained event free during
follow-up.
Follow-up data
Ten (9%) patients developed an index liver related event (4
ascites, 3 encephalopathy, 1 HCC, 2 liver related deaths), and
six patients died during the follow-up period. There were no
deaths relating to causes other than liver disease. The clinical fea-
tures of the ten patients who had at least one liver related clinical
event are detailed in Table 2.
There were no liver related events in patients with a LIF score
of less than 2 (negative predictive value 100%). Ten out of 56
(18%) patients with a LIFP2 experienced at least one liverJournal of Hepatology 201related event. Kaplan–Meier analysis showed that patients with
a LIFP3 had a significantly higher cumulative risk of developing
liver associated clinical complications and death over time, com-
pared to those with LIF <1 (p = 0.02) and LIF 1–1.99 (p = 0.03).
Furthermore, there was a strong trend towards a higher risk of
complications in those with LIF 2–2.99 compared to LIF 1–1.99
(p = 0.054, Fig. 3A).
When patients with decompensation at or prior to baseline
were excluded from the analysis, those with severe disease
(LIF 3–4) were still at an increased cumulative risk of complications
compared to those with mild disease (LIF 1–1.99; p = 0.023), and
there was a strong trend for a difference between those
with moderate disease (LIF 2–2.99) and those with mild disease
(LIF 1–1.99; p = 0.058, Fig. 3B).6 vol. 64 j 308–315 311
Table 2. Clinical features of patients who had liver related events in the follow
up period.
LIF 
score
Ishak 
stage
CP Diagnosis Index event
(months from scan)
Patient mortality
(months from 
scan)
2.5 6 B NAFLD Encephalopathy 
(15)
Yes (24)
2.7 6 A HCV HCC (11) Yes (19)
3.0 6 A HCV Encephalopathy (7) No
3.1 6 B HCV Ascites (15) No
3.5 5 A ASH Liver related death 
(3)
Yes (3)
3.5 6 A NAFLD Ascites (22) No
3.5 6 A ASH Ascites (3) Yes (4)
3.6 6 A ASH Encephalopathy (5) No
3.8 6 B NAFLD Liver related death 
(7)
Yes (7)
3.8 No 
biopsy
A ASH* Ascites (7) Yes (10)
The patient took part in the imaging study but did not attend his liver biopsy. He
had a history of excessive alcohol use suggestive of a diagnosis of alcoholic
steatohepatitis.
LIF, Liver Inflammation and Fibrosis score; CP, Child-Pugh class; NAFLD, non-
alcoholic fatty liver disease; HCV, hepatitis C; ASH, alcoholic steatohepatitis; HCC,
hepatocellular carcinoma.
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Fig. 3. Kaplan–Meier curves for liver related event free survival with patients
stratified according to Liver Inflammation and Fibrosis scores. In the entire
cohort, (A) there were significant differences between those with Liver Inflam-
mation and Fibrosis (LIF) P3 vs. LIF <1 (p = 0.02) and vs. LIF 1–1.99 (p = 0.003).
There was a strong trend towards significance between LIF 2–2.99 vs. LIF 1–1.99
(p = 0.054). Including only compensated patients at baseline, (B) there was a
significant difference between LIFP 3 vs. LIF 1–1.99 (p = 0.023) and a strong
trend towards significance between LIF 2–2.99 vs. LIF 1–1.99 (p = 0.058). (This
figure appears in colour on the web.)
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312 Journal of Hepatology 201There were no differences in the risk of developing liver
related clinical events when patients were stratified according
to MR determined severity categories for liver fat and liver iron
deposition (Fig. 4).
Cox regression analysis
LIF had a hazard ratio (HR) of 9.7 (95% CI: 2.2–43.2; p = 0.003)
when it was entered as the sole variable in the model. The HR
increased to 75.7 (95% CI: 7.6–752; p <0.001) when all 3 variables
were entered into the model. Furthermore, in the model contain-
ing all 3 variables liver fat (HR 0.80; 95% CI: 0.70–0.91; p <0.001)
and T2 which is inversely related to iron load (HR 0.87; 95% CI:
0.80–0.95; p = 0.001), had a protective effect. The results of the
Cox regression analysis with all 4 possible covariate combina-
tions including LIF are shown in Table 3.Discussion
This study shows that the LIF score, a newly established MR score
for the assessment of liver fibrosis and inflammation, strongly
predicts clinical outcomes in patients with chronic liver disease
of mixed aetiologies. No patients with LIF <2 developed liver
related clinical events, in contrast to almost 1 in 5 (18%) of thoseLow iron
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A
B
0 10 20 30 40
0
20
40
60
80
100
0 10 20 30 40
0
20
40
60
80
100
Follow-up period (months)
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
re
m
ai
ni
ng
 e
ve
nt
-fr
ee
Follow-up period (months)
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
re
m
ai
ni
ng
 e
ve
nt
-fr
ee
Fat
Iron
Fig. 4. Kaplan–Meier curves for liver related event free survival with patients
stratified according to severity of liver iron and fat. There were no significant
differences between the curves for (A) iron or (B) fat. Liver fat was categorised
according to the liver fat content measured by proton magnetic resonance
spectroscopy as 0: <1.5%, 1: 1.5% <fat <7.5% and 2: P7.5%. Liver iron was
categorised according to T2 as low iron: T2 >12.5 ms or high iron: T2 612.5 ms.
(This figure appears in colour on the web.)
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Table 3. Cox regression analysis for the prediction of liver related events for
LIF, fat and T2.
Variable HR 95% CI p value
Model 1
LIF 9.7 2.2-43.2 0.003
Model 2
LIF
Liver fat
30.5
0.95
3.3-284
0.9-1.0
0.003
0.084
Model 3
LIF
T2*
8.2
0.97
1.9-35.3
0.9-1.1
0.004
0.51
Model 4
LIF
Liver fat
T2*
75.7
0.80
0.87
7.6-752
0.70-0.91
0.80-0.95
<0.001
<0.001
0.001
LIF, Liver Inflammation and Fibrosis score; HR, hazard ratio, 95% CI: 95% confi-
dence interval.
JOURNAL OF HEPATOLOGYwith LIFP2. Quantification of liver fat and liver iron using a mul-
tiparametric MRI technique added to the predictive value of LIF.
This is the first study of liver T1 mapping to demonstrate the
prognostic value of this technique in a patient population. It fol-
lows from our previous work showing that multiparametric MR
had good diagnostic accuracy compared to histology, particularly
for the diagnosis of early disease, with an area under the receiver
operating characteristic curve of 0.94 for the identification of
those with any degree of fibrosis [22]. Other studies of similar
T1 mapping techniques have shown promise in differentiating
patients with cirrhosis from normal controls [25–27].
The enhanced ability of our technique to differentiate
between histological stages may be due to the particular quanti-
tative T1 mapping technique we apply [28], and the application of
a correction algorithm for the confounding effect of liver iron on
T1 values. The additional finding, that this T1 mapping technique
may be used to predict negative clinical outcomes, is entirely
novel. Our data included patients at all stages of fibrosis and
those with known cirrhosis. We specifically included patients
with cirrhosis since the presence of cirrhosis on a liver biopsy
is simply quantified categorically into present/absent. The advan-
tage of multiparametric MR is that this is able to quantify fibrosis
along a numeric continuum, and so stratify patients within the
category of cirrhosis into those at high risk of decompensation.
MR-quantified liver fat and liver iron did not provide any use-
ful prognostic information when these parameters were consid-
ered in isolation. However, in the multivariate analysis using
the Cox regression model, inclusion of fat and iron, added to
the predictive value of LIF increasing the HR from 9.7 to 75.7
(Table 3). Furthermore, in the model including all 3 covariates,
liver fat and T2 had a protective effect.
T2 in inversely related to iron load, therefore the protective
effect seen with decreasing liver iron (increasing T2) would be
in keeping with previous observations that increased iron is asso-
ciated with worse prognosis [29] and more aggressive NAFLD
phenotypes [30].
Previous studies have demonstrated that liver fat decreases as
fibrosis progresses [31], and also that liver fat is a risk factor for
fibrosis progression [32,33]. The observation here that liver fat is
protective, may seem at odds with the published literature. How-
ever, the most likely explanation for this finding is that patients
with high liver fat would be more likely to have early stages ofJournal of Hepatology 201fibrosis and were therefore at lower risk of disease progression
to clinical outcome within the timeframe of this study.
One other important observation from our study was that
patients with higher LIF scores had higher BMI, were more likely
to have type 2 diabetes and had higher liver fat content. Diabetes,
obesity and liver steatosis have all been associated with more
severe liver fibrosis [34–36]. In contrast to what might be
expected, in this study 26% of patients with severe disease
assessed by MR (LIFP3) and 50% of patients with moderate dis-
ease (LIF 2–2.99) had only mild fibrosis using histological staging
(Ishak 0–2). The reason for the lack of concordance, between his-
tology and MR parameters in these patients, is not clear. How-
ever, whilst this may reflect MR limitations it is equally
plausible that histology under-staged the fibrosis severity or that
these patients had an inflammatory burden that is not adequately
assessed by histology. Further work and longer follow-up is
needed to establish whether patients with mild histological fibro-
sis but high LIF (P2) scores are at increased risk progression and
decompensation compared to patients with mild histological
fibrosis and low LIF (<2) scores.
It is well documented that the lack of reliable surrogate end-
points is impacting on drug development for liver disease. Cur-
rently, clinical trials generally rely on histological assessment of
fibrosis requiring multiple biopsies over short time frames. This
is frequently unacceptable to patients so limiting recruitment,
whilst concurrently the sampling and observer dependent vari-
ability of liver biopsy will increase the number of patients
required in a study to achieve adequate statistical power to meet
the study endpoints. Furthermore in clinical practice, liver biop-
sies are usually repeated every 3–5 years to assess disease pro-
gression in patients with known chronic liver disease in order
to risk stratify patients and prioritise treatments. This has cost
implications both for health service providers and patients.
In contrast to liver biopsy, we have previously shown that
measurement of MR parameters is highly reproducible with a
coefficient of variance of 1.8% for cT1, 8.4% for T2 and 4.8% for
hepatic lipid content measured by 1H-MRS, when subjects were
scanned twice on the same day [22]. In comparison, a study of
MRE reproducibility has shown that 8.2% of the variability in
the measured liver stiffness was accounted for by the difference
between examinations on the same day [37]. The results how-
ever, are not directly comparable as different methods for the
assessment of reproducibility were used in the two studies.
In addition, iron corrected T1, T2 and liver fat content mea-
sured by 1H-MRS, are associated with their respective histological
scores [22]. Furthermore, sampling variability is minimised
through sampling of large regions of interest, and imaging the
whole liver is possible. Data from the whole organ could be cap-
tured and integrated if necessary. Lastly, this is a truly non-
invasive and quick test that could allow repeated measurements
over time and can be standardised across scanner types and mag-
net strengths. Therefore, similar to other MR biomarkers (MRE,
MRI-proton density fat fraction) [38], non-invasive, standardised
multiparametric MR could be used as a surrogate endpoint in
clinical trials, and as a clinical tool. To this effect we have demon-
strated the ability of the LIF score to predict hard clinical
outcomes.
This was a small proof of principle study that included
patients across a spectrum of liver disease severity and aetiolo-
gies. One limitation was the relatively short follow-up duration.
However, in spite of this, we were able to demonstrate a utility6 vol. 64 j 308–315 313
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for multiparametric MR in defining prognosis and the develop-
ment of clinical endpoints. These results therefore support the
further evaluation of multiparametric MR in specific patient pop-
ulations over longer follow-up periods. Since the majority of
patients included in this study were ones that had been referred
for liver biopsy by their clinical team, those with clinically evi-
dent cirrhosis, and those with no clinical suspicion for significant
liver disease may be under-represented.
Due to the relatively short follow-up, only patients with liver
cirrhosis developed complications. The inclusion of all patients in
the main analysis irrespective of the presence of decompensation
at baseline may have biased the results in the overall cohort.
However, when patients with clinically evident liver decompen-
sation were excluded from the analysis, statistically significant
differences still remained between the LIF severity groups. Fur-
thermore, seven out of the ten patients that developed complica-
tions were classified as Child-Pugh class A cirrhosis at baseline,
suggesting that the LIF score may provide valuable additional
independent prognostic data in patients with compensated liver
disease.
Therefore, of particular interest for future longitudinal studies
will be the evaluation of multiparametric MR in primary care
settings, in population screening studies of patients at risk of
metabolic syndrome and NASH (those overweight and/or with
diabetes), as is currently under investigation in the UK Biobank
population cohort, and in a larger cohort of patients with liver cir-
rhosis where non-invasive prognostic tests may me be useful in
defining appropriate timelines for liver transplantation and other
therapeutic interventions.
In conclusion, we provide the first evidence that rapid, non-
invasive multiparametric MRI technology that quantifies LIF
score in a standardised test, may provide valuable prognostic
information in patients with chronic liver disease. This finding
extends the results of our previous study demonstrating that
multiparametric MRI can be used to quantify liver fibrosis, iron
and steatosis, each known to be a critical component in driving
liver pathology. Overall, these data support the further evaluation
and development of multiparametric MR as a technology that can
be used to stage liver disease, identify patients who will progress
to cirrhosis and develop complications of liver disease. This
would enable timely clinical interventions like transplantation
and drug therapy, and facilitate clinical trials as a robust surro-
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